Argenx's Vyvgart gains commercial momentum in gMG as company plots expansion into new uses

As Argenx works to grow the reach of its up-and-coming rare disease med Vyvgart, the company is seeing significant early gains for its lone commercial product. Up next, the drugmaker plans to deploy an FDA priority review voucher to speed the med's potential expansion into a new use.